Biogen accused of over-marketing controversial new Alzheimer's drug Aduhelm

Biogen is under fire once again because of their controversial Alzheimer's drug, Aduhelm. An online survey published by the company recommends people for a cognitive screening no matter what.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news